French biotech company Aelis Farma announced positive results from a Phase 1/2 trial of its drug candidate AEF0217 for young adults with Down syndrome. The drug showed significant improvements in adaptive behavior and cognition, paving the way for potential treatments of other cognitive disorders.
Aelis Farma’s Phase 2B clinical trial for AEF0117, a potential treatment for cannabis use disorder, did not meet its primary endpoint of reducing cannabis use to one day or less per week. Indivior, which had an option to license the global rights to AEF0117, has decided not to exercise its option due to the lack of separation from placebo in the trial results.
